Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
FR901724, a Novel Anti-human Immunodeficiency Virus (HIV) Peptide Produced by Streptomyces, Shows Synergistic Antiviral Activities with HIV Protease Inhibitor and 2', 3'-Dideoxynucleosides
Hideki NAKASHIMAKohji ICHIYAMAKazuhiko INAZAWAMasahiko ITOHideya HAYASHIYutaka NISHIHARAEisaku TSUJIIToru KINO
Author information
JOURNAL FREE ACCESS

1996 Volume 19 Issue 3 Pages 405-412

Details
Abstract

A novel tricyclic 21-amino-acid peptide, FR901724, was isolated from the cultured broth of Streptomyces sp. No. 73264. This peptide appears to possess potent anti-human immunodeficiency virus (HIV) activity in vitro and might represent a lead to a new class of anti-HIV agents ; it qualifies as an HIV-cell fusion inhibitor because of its weak inhibition of virus-cell binding and strong inhibition of syncytium formation. From the time-of-addition experiments, the mode of action of FR901724 was found to definitely differ from that of KNI-272, a peptide mimetic allophenylnorstatine-derivative HIV protease inhibitor. FR901724 appears to interact with a stage of the virus replicative cycle that may well correspond to virus-cell fusion. We also found that FR901724 was synergistic or had a strong tendency toward synergism when combined with other antiviral drugs, such as KNI-272, AZT, ddI and dextran sulfate.

Content from these authors
© The Pharmaceutical Society of Japan
Previous article Next article
feedback
Top